<DOC>
	<DOC>NCT02361619</DOC>
	<brief_summary>Four periods of oral dosing following overnight fasting (1. known metabolic probe drug cocktail consisting of caffeine, diclofenac, esomeprazole, metoprolol, midazolam; 2. dabigatran + cocktail; 3. dabigatran alone; 4. clarithromycin 3 days + cocktail + dabigatran). Blood samples collected for pharmacokinetics over 24 h. Washout between periods. Adverse events, haematology and clinical chemistry recorded.</brief_summary>
	<brief_title>Dabigatran in an Interaction Probe Drug Cocktail</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy Weight at least 50 kg and body mass index 19 30 kg m2 Normal clinical laboratory profiles No childbearing potential or use of adequate contraceptive measures Blood loss &gt;300 ml within 2 months prior to the first dosing day Pregnancy, breastfeeding Allergy or hypersensitivity to caffeine, diclofenac, esomeprazole, metoprolol, midazolam, dabigatran or clarithromycin or to excipients in the pharmaceutical products Infection with HIV, HBV or HCV Participation in the preceding 3 months or concomitantly in any clinical drug study Suspected current drug or alcohol abuse History of drug or alcohol abuse. Concomitant medication with the exception of hormonal contraception. Positive result in urine test for drug abuse. Nicotine consumption equivalent to &gt;5 cigarettes per day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>